EAU guidelines on testicular cancer: 2011 update
Standard
EAU guidelines on testicular cancer: 2011 update. / Albers, Peter; Albrecht, Walter; Algaba, Ferran; Bokemeyer, Carsten; Cohn-Cedermark, Gabriella; Fizazi, Karim; Horwich, Alan; Laguna, Maria Pilar; European Association of Urology.
In: EUR UROL, Vol. 60, No. 2, 2, 01.08.2011, p. 304-319.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - EAU guidelines on testicular cancer: 2011 update
AU - Albers, Peter
AU - Albrecht, Walter
AU - Algaba, Ferran
AU - Bokemeyer, Carsten
AU - Cohn-Cedermark, Gabriella
AU - Fizazi, Karim
AU - Horwich, Alan
AU - Laguna, Maria Pilar
AU - European Association of Urology
N1 - Copyright © 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.
PY - 2011/8/1
Y1 - 2011/8/1
N2 - CONTEXT: On behalf of the European Association of Urology (EAU), guidelines for the diagnosis, therapy, and follow-up of testicular cancer were established.OBJECTIVE: This article is a short version of the EAU testicular cancer guidelines and summarises the main conclusions from the guidelines on the management of testicular cancer.EVIDENCE ACQUISITION: Guidelines were compiled by a multidisciplinary guidelines working group. A systematic review was carried out using Medline and Embase, also taking Cochrane evidence and data from the European Germ Cell Cancer Consensus Group into consideration. A panel of experts weighted the references, and a level of evidence and grade of recommendation were assigned.RESULTS: There is a paucity of literature especially regarding longer term follow-up, and results from a number of ongoing trials are awaited. The choice of treatment centre is of the utmost importance, and treatment in reference centres within clinical trials, especially for poor-prognosis nonseminomatous germ cell tumours, provides better outcomes. For patients with clinical stage I seminoma, based on recently published data on long-term toxicity, adjuvant radiotherapy is no longer recommended as first-line adjuvant treatment. The TNM classification 2009 is recommended.CONCLUSIONS: These guidelines contain information for the standardised management of patients with testicular cancer based on the latest scientific insights. Cure rates are generally excellent, but because testicular cancer mainly affects men in their third or fourth decade of life, treatment effects on fertility require careful counselling of patients, and treatment must be tailored taking individual circumstances and patient preferences into account.
AB - CONTEXT: On behalf of the European Association of Urology (EAU), guidelines for the diagnosis, therapy, and follow-up of testicular cancer were established.OBJECTIVE: This article is a short version of the EAU testicular cancer guidelines and summarises the main conclusions from the guidelines on the management of testicular cancer.EVIDENCE ACQUISITION: Guidelines were compiled by a multidisciplinary guidelines working group. A systematic review was carried out using Medline and Embase, also taking Cochrane evidence and data from the European Germ Cell Cancer Consensus Group into consideration. A panel of experts weighted the references, and a level of evidence and grade of recommendation were assigned.RESULTS: There is a paucity of literature especially regarding longer term follow-up, and results from a number of ongoing trials are awaited. The choice of treatment centre is of the utmost importance, and treatment in reference centres within clinical trials, especially for poor-prognosis nonseminomatous germ cell tumours, provides better outcomes. For patients with clinical stage I seminoma, based on recently published data on long-term toxicity, adjuvant radiotherapy is no longer recommended as first-line adjuvant treatment. The TNM classification 2009 is recommended.CONCLUSIONS: These guidelines contain information for the standardised management of patients with testicular cancer based on the latest scientific insights. Cure rates are generally excellent, but because testicular cancer mainly affects men in their third or fourth decade of life, treatment effects on fertility require careful counselling of patients, and treatment must be tailored taking individual circumstances and patient preferences into account.
KW - Adult
KW - Humans
KW - Male
KW - Middle Aged
KW - Europe
KW - Predictive Value of Tests
KW - Prognosis
KW - Neoplasm Staging
KW - Evidence-Based Medicine
KW - Societies, Medical/standards
KW - Testicular Neoplasms/diagnosis/pathology/therapy
KW - Urology/standards
KW - Adult
KW - Humans
KW - Male
KW - Middle Aged
KW - Europe
KW - Predictive Value of Tests
KW - Prognosis
KW - Neoplasm Staging
KW - Evidence-Based Medicine
KW - Societies, Medical/standards
KW - Testicular Neoplasms/diagnosis/pathology/therapy
KW - Urology/standards
U2 - 10.1016/j.eururo.2011.05.038
DO - 10.1016/j.eururo.2011.05.038
M3 - SCORING: Journal article
C2 - 21632173
VL - 60
SP - 304
EP - 319
JO - EUR UROL
JF - EUR UROL
SN - 0302-2838
IS - 2
M1 - 2
ER -
